VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study

Shares plunged 37% after Valneva reported its Lyme vaccine achieved >70% efficacy but failed to meet a key statistical endpoint, raising regulatory and approval-path concerns. The miss clouds the company’s near-term prospects despite plans to proceed with regulatory filings and increases investor uncertainty around commercialization and timing.

Analysis

Shares plunged 37% after Valneva reported its Lyme vaccine achieved >70% efficacy but failed to meet a key statistical endpoint, raising regulatory and approval-path concerns. The miss clouds the company’s near-term prospects despite plans to proceed with regulatory filings and increases investor uncertainty around commercialization and timing.